Inspra (Eplerenone) - Summary

INSPRA SUMMARY

INSPRA^®

(eplerenone) tablets

INSPRA^™ contains eplerenone, a blocker of aldosterone binding at the mineralocorticoid receptor.

INSPRA is indicated to improve survival of stable patients with left ventricular systolic dysfunction (ejection fraction CLINICAL STUDIES, Congestive Heart Failure Post-Myocardial Infarction.)

INSPRA is indicated for the treatment of hypertension. INSPRA may be used alone or in combination with other antihypertensive agents. (See CLINICAL STUDIES, Hypertension.)

INSPRA NEWS HIGHLIGHTS

Published Studies Related to Inspra (Eplerenone)

A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. [2008.08]

Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. [2008.03]

Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. [2008.02]

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. [2006.09]

Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30%. [2006.05]

more>>

Clinical Trials Related to Inspra (Eplerenone)

The Long-Term Study to Evaluate the Safety of Eplerenone in the Treatment of Hypertension in Children Aged 6 to 16 Years [Completed]

A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children. [Completed]

Effects of Eplerenone on Left Ventricular Remodelling Following Heart Attack [Completed]

The Effect of Eplerenone and Atorvastatin on Markers of Collagen Turnover in Diastolic Heart Failure [Recruiting]

CMR to Assess Fibrosis in Cardiomyopathy Using Eplerenone [Recruiting]

more>>